Kairos Pharma, LTD.

Kairos Pharma announced the acquisition of worldwide rights for CL-741, a Phase 1-ready c-MET kinase inhibitor targeting EGFR-mutated lung cancer, from Celyn Therapeutics. This addition expands its oncology pipeline, which includes ENV-105, KROS-201, KROS-102, and ENV-205. The company also outlined key milestones for the remainder of 2026, including initiating a Phase 1 study for CL-741 and advancing clinical trials for ENV-105.

Kairos Pharma, Ltd. announced its 2026 Annual Meeting of Stockholders on June 29, 2026, where shareholders will vote on several key proposals. These include the election of four directors, the ratification of Weinberg & Company, P.A. as independent auditors, and an advisory vote on executive compensation. The most significant proposals involve approving an amendment to the Certificate of Incorporation to effect a reverse stock split with a ratio between 1:3 and 1:250, and an amendment to the 2023 Equity Incentive Plan to increase available shares by 5,000,000 and add an evergreen provision.

Kairos Pharma, Ltd. announced the issuance of a new investor presentation on May 18, 2026. The presentation will be available on the company's website and will be delivered by CEO John Yu at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation aims to provide updates on the company's clinical program and partnering activities.

Kairos Pharma, Ltd. reported a net loss of $1.65 million for the three months ended March 31, 2026, an increase from $1.26 million in the prior year. The company had no revenue and its cash and cash equivalents decreased to $3.68 million from $4.49 million at the end of 2025. The filing also highlighted substantial doubt about the company's ability to continue as a going concern, with existing cash potentially insufficient for the next 12 months.